CoChat
Sign Up
Cited by 140

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

Gabay, Cem, McInnes, Iain B, Kavanaugh, Arthur, Tuckwell, Katie, Klearman, Micki, Pulley, Jennifer, Sattar, Naveed·2016·Annals of the Rheumatic Diseases
DOI 10.1136/annrheumdis-2015-207872PMC PMC5036214
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2015-207872

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Change from baseline to week 8 in HDL-SAA (A, bio-repository population), sPLA2 IIA (B, bio-repository population) and Lp(a) (C, safety population)—patient-level data. ADA, adalimumab; HDL-SAA, high-density lipoprotein-associated serum amyloid A; IV, intravenous; Lp(a), lipoprotein (a); sPLA2 IIA, secretory phospholipase A2 IIA; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.
Figure 1 Change from baseline to week 8 in HDL-SAA (A, bio-repository population), sPLA2 IIA (B, bio-repository population) and Lp(a) (C, safety population)—patient-level data. ADA, adalimumab; HDL-SAA, high-density lipoprotein-associated serum amyloid A; IV, intravenous; Lp(a), lipoprotein (a); sPLA2 IIA, secretory phospholipase A2 IIA; q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 35

  1. Solomon, 2006, Patterns of cardiovascular risk in rheumatoid arthritis, Ann Rheum Dis, 65, 1608, 10.1136/ard.2005.050377 · DOI
  2. Aviña-Zubieta, 2008, Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies, Arthritis Rheum, 59, 1690, 10.1002/art.24092 · DOI
  3. del Rincón, 2001, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors, Arthritis Rheum, 44, 2737, 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-# · DOI
  4. Sattar, 2003, Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis, Circulation, 108, 2957, 10.1161/01.CIR.0000099844.31524.05 · DOI
  5. Myasoedova, 2011, Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease, Ann Rheum Dis, 70, 482, 10.1136/ard.2010.135871 · DOI
  6. Kugiyama, 1999, Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease, Circulation, 100, 1280, 10.1161/01.CIR.100.12.1280 · DOI
  7. Mallat, 2007, Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study, Arterioscler Thromb Vasc Biol, 27, 1177, 10.1161/ATVBAHA.107.139352 · DOI
  8. Robertson, 2013, Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm, Nat Rev Rheumatol, 9, 513, 10.1038/nrrheum.2013.91 · DOI
  9. Lee, 2000, Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis, Clin Rheumatol, 19, 324, 10.1007/PL00011174 · DOI
  10. Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604 · DOI · Paper page
  11. Kamstrup, 2012, Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis, Arterioscler Thromb Vasc Biol, 32, 1732, 10.1161/ATVBAHA.112.248765 · DOI
  12. Boffa, 2013, Update on lipoprotein(a) as a cardiovascular risk factor and mediator, Curr Atheroscler Rep, 15, 360, 10.1007/s11883-013-0360-6 · DOI
  13. Choy, 2009, Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions, Ann Rheum Dis, 68, 460, 10.1136/ard.2008.101964 · DOI
  14. McInnes, 2015, Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study, Ann Rheum Dis, 74, 694, 10.1136/annrheumdis-2013-204345 · DOI
  15. Daïen, 2012, Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis, Ann Rheum Dis, 71, 862, 10.1136/annrheumdis-2011-201148 · DOI
  16. Popa, 2005, Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis, Ann Rheum Dis, 64, 303, 10.1136/ard.2004.023119 · DOI
  17. Wijbrandts, 2009, Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis, Ann Rheum Dis, 68, 1316, 10.1136/ard.2007.086728 · DOI
  18. Cauza, 2002, Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis, Wien Klin Wochenschr, 114, 1004
  19. Seriolo, 2006, Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis, Ann N Y Acad Sci, 1069, 414, 10.1196/annals.1351.039 · DOI
  20. Hjeltnes, 2013, Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-alpha-inhibitor, Clin Exp Rheumatol, 31, 415
  21. Sattar, 2007, Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study, Arthritis Rheum, 56, 831, 10.1002/art.22447 · DOI
  22. Gabay, 2013, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial, Lancet, 381, 1541, 10.1016/S0140-6736(13)60250-0 · DOI · Paper page
  23. Schiff, 2011, Integrated safety in tocilizumab clinical trials, Arthritis Res Ther, 13, R141, 10.1186/ar3455 · DOI
  24. Chiba, 1992, A rapid and simple quantification of human apolipoprotein E-rich high-density lipoproteins in serum, Biochem Med Metabolic Biol, 47, 31, 10.1016/0885-4505(92)90005-J · DOI
  25. Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386 · DOI · Paper page
  26. Charles-Schoeman, 2015, Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib, Arthritis Rheumatol, 67, 616, 10.1002/art.38974 · DOI
  27. Jahangiri, 2009, HDL remodeling during the acute phase response, Arterioscler Thromb Vasc Biol, 29, 261, 10.1161/ATVBAHA.108.178681 · DOI
  28. Rohrer, 2004, High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease, Curr Opin Lipidol, 15, 269, 10.1097/00041433-200406000-00006 · DOI
  29. Chait, 2005, Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?, J Lipid Res, 46, 389, 10.1194/jlr.R400017-JLR200 · DOI
  30. Müller, 2015, IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans, J Lipid Res, 56, 1034, 10.1194/jlr.P052209 · DOI
  31. Smolen, 2012, Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction, Ann Rheum Dis, 71, 687, 10.1136/annrheumdis-2011-200395 · DOI
  32. Jamnitski, 2013, High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study, J Rheumatol, 40, 825, 10.3899/jrheum.121358 · DOI
  33. Westlake, 2011, Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review, Rheumatology (Oxford), 50, 518, 10.1093/rheumatology/keq316 · DOI
  34. Barnabe, 2011, Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis, Arthritis Care Res, 63, 522, 10.1002/acr.20371 · DOI
  35. Rao, 2015, An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy, Arthritis Rheumatol, 67, 372, 10.1002/art.38920 · DOI

Cited by

Sorted by citations

See all 140

Metadata

Authors
Gabay, C., McInnes, I. B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., & Sattar, N.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2016-10
Volume
75
Issue
10
Pages
1806-1812
ISSN
0003-4967
DOI
10.1136/annrheumdis-2015-207872
PMC
PMC5036214
Cited by
140
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2015-207872
The paper
Gabay, C., McInnes, I. B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., & Sattar, N. (2016). Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-207872